Avalglucosidase Alfa Pregnancy Study
← catalyst calendarNCT05734521 · readout in 2,265 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
100estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-26 | actual | When the study began enrolling |
| Primary completion | 2032-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pompe Disease
- Pregnancy
Interventions
- Biological: avalglucosidase alfa-NGPT (GZ402666) IV — also filed as NEXVIAZYME
- Biological: avalglucosidase alfa-NGPT (GZ402666) — also filed as NEXVIAZYME
Primary outcomes
what the primary-completion date above is the date OFMaternal complications
measured through study completion, an average of 10 years
Pregnancy outcome
measured through study completion, an average of 10 years
Infant outcome
measured through study completion, an average of 10 years
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed